Ueshima S, Silence K, Collen D, Lijnen H R
Center for Molecular and Vascular Biology, University of Leuven, Belgium.
Thromb Haemost. 1993 Sep 1;70(3):495-9.
Recombinant staphylokinase (STAR) is produced as a 136 amino acid protein with NH2-terminal sequence Ser-Ser-Ser (mature STAR, HMW-STAR), which may be converted to lower molecular weight forms (LMW-STAR) by removal of the first six residues (yielding STAR-delta 6 with NH2-terminal Gly-Lys-Tyr-) or the first ten residues (yielding STAR-delta 10 with NH2-terminal Lys-Gly-Asp-). In the present study the occurrence and effects of these conversions during plasminogen activation by HMW-STAR were studied in purified systems and in human plasma. In stoichiometric mixtures of HMW-STAR and native human plasminogen (Glu-plasminogen), rapid and quantitative conversion of HMW-STAR to LMW-STAR occurred, concomitant with exposure of the active site in the plasmin-STAR complex. NH2-terminal amino acid sequence analysis revealed the sequence Lys-Gly-Asp- in addition to the known sequences of the Lys-plasmin chains, identifying STAR-delta 10 as the derivative generated from HMW-STAR. In mixtures of catalytic amount of HMW-STAR and human plasminogen, plasmin generation occurred progressively, following an initial lag phase, during which HMW-STAR was converted to LMW-STAR. Plasmin-mediated conversion of HMW-STAR to LMW-STAR obeyed Michaelis-Menten kinetics with Km = 3.6 microM and k2 = 0.38 s-1. The specific clot lysis activities of HMW-STAR (122,000 +/- 8,000 units/mg) and LMW-STAR (129,000 +/- 8,000 units/mg) were indistinguishable. In an in vitro system consisting of a 60 microliters plasma clot submerged in 250 microliters plasma, 80% clot lysis within 1 h was obtained with 70 nM HMW-STAR.(ABSTRACT TRUNCATED AT 250 WORDS)
重组葡激酶(STAR)作为一种含136个氨基酸的蛋白质产生,其氨基末端序列为Ser-Ser-Ser(成熟STAR,HMW-STAR),通过去除前六个残基(产生氨基末端为Gly-Lys-Tyr-的STAR-δ6)或前十个残基(产生氨基末端为Lys-Gly-Asp-的STAR-δ10)可转化为较低分子量形式(LMW-STAR)。在本研究中,在纯化系统和人血浆中研究了HMW-STAR激活纤溶酶原过程中这些转化的发生情况及其影响。在HMW-STAR与天然人纤溶酶原(Glu-纤溶酶原)的化学计量混合物中,HMW-STAR迅速且定量地转化为LMW-STAR,同时纤溶酶-STAR复合物中的活性位点暴露。氨基末端氨基酸序列分析除了揭示Lys-纤溶酶链的已知序列外,还发现了序列Lys-Gly-Asp-,确定STAR-δ10是由HMW-STAR产生的衍生物。在催化量的HMW-STAR与人纤溶酶原的混合物中,纤溶酶的产生在初始延迟期后逐渐发生,在此期间HMW-STAR转化为LMW-STAR。纤溶酶介导的HMW-STAR向LMW-STAR的转化遵循米氏动力学,Km = 3.6 microM,k2 = 0.38 s-1。HMW-STAR(122,000 +/- 8,000单位/毫克)和LMW-STAR(129,000 +/- 8,000单位/毫克)的特异性凝块溶解活性无明显差异。在一个由60微升血浆凝块浸没在250微升血浆中的体外系统中,70 nM HMW-STAR在1小时内可实现80%的凝块溶解。(摘要截短于250字)